Every Form 4 that BioVie, Inc. (BIVI) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow BIVI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BIVI filings page.
BIOVIE INC. (BIVI) reported that Chief Medical Officer Joseph M. Palumbo purchased common stock. On 2026-08-28 he bought 4,843 shares of common stock in open market transactions at $2.16 per share, bringing his directly held position to 6,036 shares.
The shares were acquired in several open market trades, all executed at the same price.
BIOVIE INC. (BIVI) director Amy Suzon Chappell purchased 727 shares of Common Stock on 2026-08-28 in an open market transaction at $2.16 per share. Following this reported transaction, she directly owns 727 shares of BIOVIE INC. common stock.
BIOVIE INC. (BIVI) reported that its Chief Financial Officer, Joanne Wendy Kim, purchased 2,500 shares of common stock in an open market transaction on 2026-08-28 at a price of $2.18 per share. Following this purchase, she directly holds 3,441 shares of BIOVIE INC. common stock.
BIOVIE INC. (BIVI) reported that President & CEO Cuong V. Do purchased common stock on August 27, 2026. He bought 15,210 shares of BioVie common stock in open market transactions at a weighted average price of $2.08 per share, with trade prices ranging from $2.05 to $2.10. Following this purchase, he directly holds 16,117 common shares of BioVie.
BioVie Inc. reported that Chief Medical Officer Joseph M. Palumbo received a grant of 132,000 stock options on January 5, 2026.
The options, held directly, have an exercise price of $1.31 per share, were granted at no cost, and are exercisable for 132,000 shares of common stock. According to the vesting schedule, 55% of the options vested on January 5, 2026, with the remaining options vesting in three equal installments on January 5, 2027, January 5, 2028, and January 5, 2029. Any unexercised options expire on January 5, 2036.
BioVie Inc. reported that its Chief Financial Officer, Joanne Wendy Kim, received a grant of stock options on January 5, 2026. The award covers 110,100 stock options with an exercise price of $1.31 per share, giving her the right to buy BioVie common stock at that price in the future. The filing shows she directly holds all 110,100 options after this transaction.
According to the vesting schedule, 55% of the options vested on January 5, 2026, meaning more than half became exercisable immediately. The remaining options are set to vest in three equal installments on January 5, 2027, January 5, 2028, and January 5, 2029, aligning her long-term incentives with the company’s performance over several years.
BioVie Inc. director Sigmund Rogich reported new option grants. On January 5, 2026, he was awarded stock options covering 70,000 shares and an additional 141,100 shares of BioVie common stock, each with an exercise price of $1.31 per share.
The 70,000-share option grant vests in four equal installments on February 11, 2026, May 11, 2026, August 11, 2026, and the earlier of November 11, 2026 and the company’s 2026 annual shareholders’ meeting. For the 141,100-share grant, 75% vested on January 5, 2026, with the remaining options vesting in three equal installments on January 5, 2027, January 5, 2028, and January 5, 2029.
BioVie Inc. reported an insider equity award connected to its President & CEO, Cuong V Do. On January 5, 2026, Do & Rickles Investments LLC, an entity associated with him, was granted a stock option to buy 665,300 shares of BioVie common stock at an exercise price of $1.31 per share. The option was reported as an indirect holding.
According to the vesting terms, 55% of the options vested on January 5, 2026, with the remaining balance vesting in three equal installments on January 5, 2027, January 5, 2028, and January 5, 2029. The filing shows a grant price of $0 for the derivative security itself, which reflects that this was an option award rather than an open‑market purchase.
BioVie Inc. director Michael Edward Sherman received new stock option awards. On January 5, 2026, he was granted stock options to purchase 80,000 shares of BioVie common stock at an exercise price of $1.31 per share, expiring on January 5, 2031. These options vest in four equal installments on February 11, 2026, May 11, 2026, August 11, 2026 and the earlier of November 11, 2026 and the date of the company’s 2026 annual shareholders’ meeting.
On the same date, he was also granted stock options to purchase 341,100 shares of common stock at the same $1.31 exercise price, also expiring on January 5, 2031. For this grant, 75% of the options vested on January 5, 2026, with the remaining 25% vesting in three equal installments on January 5, 2027, January 5, 2028 and January 5, 2029. Both grants are reported as directly owned.
BioVie Inc. director Kameel D. Farag received a grant of 57,500 stock options on January 5, 2026. The options have an exercise price of $1.31 per share and, if not exercised, expire on January 5, 2031. Each option is exercisable for one share of BioVie common stock, giving Farag the right to buy up to 57,500 shares.
According to the vesting terms, 7,500 options vest on the grant date, while the remaining options vest in four equal installments on February 11, 2026, May 11, 2026, August 11, 2026, and the earlier of November 11, 2026 and the company’s 2026 annual shareholders’ meeting. After this grant, Farag beneficially holds 57,500 derivative securities in the form of these stock options.
BioVie Inc. director Amy Suzon Chappell reported receiving a stock option grant on January 5, 2026. The award covers options to purchase 57,500 shares of BioVie common stock at an exercise price of $1.31 per share, with no cash paid for the grant itself.
According to the vesting terms, 7,500 shares underlying the options vest on the grant date. The remaining options vest in four equal installments on February 11, 2026, May 11, 2026, August 11, 2026, and on the earlier of November 11, 2026 and the date of BioVie’s 2026 annual shareholders’ meeting. The options expire on January 5, 2031 if not exercised.
BioVie Inc. director James Paul Lang reported new stock option awards. On January 5, 2026, he received two grants of stock options to buy BioVie common stock at an exercise price of $1.31 per share, one covering 90,000 shares and another covering 330,500 shares, both expiring on January 5, 2031.
The 90,000-share option vests in four equal installments on February 10, 2026, May 11, 2026, August 11, 2026 and the earlier of November 11, 2026 and the date of BioVie’s 2026 annual shareholders’ meeting. For the 330,500-share option, 75% vested on January 5, 2026, with the remaining portion vesting in three equal installments on January 5, 2027, January 5, 2028 and January 5, 2029. Both awards are held directly by the director and were reported as acquisitions of derivative securities.